| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a423b3896fb137308c231f90d9a6e6e0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0368
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate |
2017-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46e78d7167a0233e8da2ed07c29521f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5663fab3973b9ca6c86ed9a303fc01b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76bc03c8826ff981c4c5d6fea6f6a272 |
| publicationDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018369327-A1 |
| titleOfInvention |
Method for treating or preventing osteoarthritis |
| abstract |
A method for treating or preventing osteoarthritis includes promoting the expression of STAMP2 in chondrocyte. Osteoarthritis is diagnosed by measuring an expression level of STAMP2 or an amount of STAMP2 protein in chondrocyte, and comparing the measured results with that in a control sample. A therapeutic agent for osteoarthritis is screened by treating chondrocyte with a candidate agent, measuring an expression level of STAMP2 or an amount of STAMP2 protein in the chondrocyte, and identifying a candidate agent as the therapeutic agent when the measured expression level of STAMP2 or the measured amount of STAMP2 protein is increased in the chondrocyte as compared to the chondrocyte before treatment with the candidate agent. Measuring the expression level of STAMP2 or the amount of extracellularly secreted STAMP2 protein is highly useful for diagnosing osteoarthritis in a rapid and convenient manner using a biological sample such as blood. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200098255-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102275313-B1 |
| priorityDate |
2017-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |